42 completed, 6 terminated, 2 not yet recruiting, 2 recruiting. 19 Phase 3, 14 Phase 2, 10 Phase 4, 4 Not applicable, 2 Phase 1.
Follow Chronic Plaque Psoriasis: new trials by email Literature Review of Chronic Plaque Psoriasis trials Research Report on Chronic Plaque Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparative Study on Unani Formulation Vs Active Control in Plaque Psoriasis Marham Asfedaj, Mundij wa Mushil Sawda (Unani Oral decoction), Coal tar 1% & Salicylic acid 3 % solution - Chronic Plaque Psoriasis, Plaque Psoriasis | Phase 2 | Not yet recruiting | National Institute of Unani Medicine, Bengaluru | 54 | 2027-04-01 | 2026-09-25 |
| An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis Roflumilast 0.3% topical cream - Chronic Plaque Psoriasis, Nail Psoriasis | Phase 4 | Recruiting | Modern Research Associates, PLLC | 15 | 2026-09-15 | 2026-10-01 |
| Comparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis Methotrexate, Tofacitinib - Chronic Plaque Psoriasis | Not applicable | Not yet recruiting | Pak Emirates Military Hospital | 88 | 2026-06-01 | 2026-05-12 |
| To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital Methotrexate, Apremilast - Chronic Plaque Psoriasis | Early Phase 1 | Recruiting | Syeda Sana Zaman | 106 | 2025-12-25 | 2026-01-13 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis Placebo, Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 133 | 2023-10-31 | 2026-06-26 |
| Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis Tildrakizumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Nail Psoriasis | Phase 3 | Completed | Sun Pharmaceutical Industries Limited | 99 | 2021-05-13 | 2026-04-01 |
| Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Topical roflumilast - Chronic Plaque Psoriasis | Phase 3 | Completed | Arcutis Biotherapeutics, Inc. | 337 | 2020-02-12 | 2026-09-09 |
| Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test BOS-475, Active ingredient-free vehicle cream, Daivonex cream (calcipotriol 0.005%) - Chronic Plaque Psoriasis | Phase 1 | Completed | Boston Pharmaceuticals | 15 | 2020-01-06 | 2020-11-18 |
| Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Roflumilast 0.3% cream, Vehicle Cream - Chronic Plaque Psoriasis | Phase 3 | Completed | Arcutis Biotherapeutics, Inc. | 439 | 2019-12-20 | 2022-12-07 |
| Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis ARQ-151 0.3% cream, ARQ-151 vehicle cream - Chronic Plaque Psoriasis | Phase 3 | Completed | Arcutis Biotherapeutics, Inc. | 442 | 2019-12-17 | 2022-12-07 |
| Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis Chronic Plaque Psoriasis | Completed | AbbVie | 2759 | 2019-07-01 | 2025-11-17 | |
| A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 172 | 2018-12-20 | 2025-07-14 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 1353 | 2018-09-05 | 2026-04-15 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab, Secukinumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 743 | 2018-06-13 | 2026-04-15 |
| A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 435 | 2018-02-05 | 2026-04-15 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab, Adalimumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 478 | 2018-01-26 | 2026-04-15 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Bimekizumab, Ustekinumab, Placebo - Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis | Phase 3 | Completed | UCB Biopharma SRL | 567 | 2017-12-06 | 2026-04-15 |
| A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis Bimekizumab - Chronic Plaque Psoriasis | Phase 2 | Completed | UCB Biopharma SRL | 43 | 2017-07-03 | 2022-07-22 |
| A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis Bimekizumab, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | UCB Biopharma SRL | 49 | 2016-12-27 | 2026-03-24 |
| A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis Bimekizumab, Placebo - Chronic Plaque Psoriasis | Phase 2 | Completed | UCB Biopharma SRL | 217 | 2016-12-14 | 2022-10-18 |
Showing 20 of 54. Sign in to see all of them.
Psoriasis (26) · Skin Diseases (4) · Arthritis, Psoriatic (2) · Dermatitis (2) · Plaque, Amyloid (2) · Autoimmune Diseases (1) · Margins of Excision (1) · Obesity (1)
Skin and Connective Tissue Diseases (28) · Skin Diseases, Papulosquamous (26) · Skin Diseases (24) · Pathological Conditions, Signs and Symptoms (4) · Arthritis (2) · Bone Diseases (2) · Joint Diseases (2) · Musculoskeletal Diseases (2) · Pathological Conditions, Anatomical (2) · Spinal Diseases (2) · Spondylarthritis (2) · Spondylarthropathies (2) · Spondylitis (2) · Body Weight (1) · Immune System Diseases (1)
bimekizumab (11) · Alefacept (8) · secukinumab (5) · Adalimumab (3) · Roflumilast (3) · Methotrexate (2) · apremilast (2) · calcipotriene (2) · efalizumab (2) · Acitretin (1) · Calcitriol (1) · Caloric Restriction (1) · Certolizumab Pegol (1) · Coal Tar (1) · Cyclosporine (1)
UCB Biopharma SRL (10) · Novartis Pharmaceuticals (5) · Astellas Pharma Inc (4) · Arcutis Biotherapeutics, Inc. (3) · Merck KGaA, Darmstadt, Germany (3) · AbbVie (2) · Pfizer (2) · Universita di Verona (2) · Abbott (1) · Biogen (1) · Boston Pharmaceuticals (1) · Charite University, Berlin, Germany (1) · Duke University (1) · Eisai Inc. (1) · Galderma R&D (1)
United States (31) · Canada (26) · Germany (16) · Poland (11) · Australia (10) · United Kingdom (9) · France (8) · Hungary (8) · Italy (8) · Austria (6) · Belgium (6) · Czechia (6) · Japan (5) · Netherlands (5) · Spain (5)
David Berk, MD (2) · Giampiero Girolomoni (2) · John C Murray, MD (2) · Nicole Selenko-Gebauer, MD (2) · Alexandra B Kimball, MD (1) · Barbara White, M.D. (1) · Barry Ticho, MD (1)
PMID 35544084, PMID 39578348, PMID 41060492, PMID 41580158, PMID 41800601, PMID 36751950, PMID 37950894, PMID 40286813, PMID 40886218, PMID 41359217, PMID 34260044, PMID 36125472, PMID 36422852, PMID 36689515, PMID 38588819, PMID 41134450, PMID 18996858, PMID 20513160, PMID 20713833, PMID 22413944, PMID 23178916, PMID 25007392, PMID 26267726, PMID 27573260, PMID 27576559, PMID 28815476, PMID 29171393, PMID 30113844, PMID 30972746, PMID 32088207, PMID 32311398, PMID 32473974, PMID 33549192, PMID 33549193, PMID 33748660, PMID 33891379, PMID 33891380, PMID 34001692, PMID 34110605, PMID 34471992, PMID 34687214, PMID 35133113, PMID 35286612, PMID 35305260, PMID 36045513, PMID 36648594, PMID 37182701, PMID 37315881, PMID 37341961, PMID 39285121
2016 (9), 2005 (1), 2017 (1), 2019 (1)